GlassScriptPhysician profile
Jacob C Schultz
NPI 1063031987
$1,760.88
in general payments reported to CMS, 2019-2025
32 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.08 · 2023: $188 · 2024: $844 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $230.75 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $164.93 | 2023-2025 | Airsupra, Breztri |
| Dexcom, INC. | $162.28 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $149.53 | 2023-2025 | Avycaz |
| Novo Nordisk INC | $113.05 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $101.00 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $85.64 | 2024-2025 | |
| Corium, LLC | $64.79 | 2024-2025 | Azstarys |
| Corcept Therapeutics | $64.02 | 2024-2025 | Korlym |
| Neos Therapeutics, LP | $62.62 | 2024-2025 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $47.41 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Novartis Pharmaceuticals Corporation | $46.26 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.34 | 2025 | Relistor, Xifaxan |
| Phathom Pharmaceuticals, INC. | $36.03 | 2025 | Voquezna |
| Amgen INC. | $32.98 | 2024-2025 | Krystexxa, Otezla, Repatha |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.94 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $29.87 | 2024-2025 | Vaxneuvance, Vaxelis, Capvaxive |
| Exact Sciences Corporation | $25.03 | 2024 | Cologuard Collection Kit |
| Verona Pharma, INC. | $24.23 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $20.19 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.84 | 2024 | |
| Glaxosmithkline, LLC. | $18.25 | 2024 | Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $17.95 | 2025 | Auvelity |
| Vivus LLC | $17.71 | 2023 | Qsymia |
| Esperion Therapeutics, INC. | $17.49 | 2025 | Nexletol |
| Shield Therapeutics INC | $16.11 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.55 | 2024 | Trintellix |
| Amneal Pharmaceuticals LLC | $14.96 | 2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.23 | 2024 | Jardiance |
| Tolmar, INC. | $13.64 | 2024 | |
| Irhythm Technologies, INC. | $13.60 | 2024 | Zio Xt Patch, Zio Monitor |
| Organon LLC | $13.58 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.